Metabolic Disease
| 5 min read
The Synthetic Molecule Process Innovation Phorum brings together major pharma companies, regulators, and CDMOs to build consensus on pressing challenges in small molecule manufacturing. 
| 6 min read
Long framed as a gynecological condition, PMOS is now understood as a multisystem disorder with metabolic, psychological, and cardiovascular consequences.
| 3 min read
It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis.
| 4 min read
FDA leadership changes, pharma deals, clinical trials, and more led the news this week.
| 6 min read
Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results.
| 5 min read
Advances in high-throughput experimentation and machine learning are helping researchers map how gut microbes influence drug response and health outcomes.
| 4 min read
A new study shows how specific gut bacteria work with diet to trigger fat browning in mice, revealing potential pathways for future metabolic therapies.
| 4 min read
Legal battles, FDA setbacks, billion-dollar bets, and more led the news this week.
| 4 min read
These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
